生命科学企业出海BD税务筹划——支柱二影响网络研讨会

Core Insights - The Chinese life sciences industry is showcasing its innovative capabilities and is increasingly engaging in outbound business development (BD) activities, despite facing challenges from global tax rule changes and complex tax issues [1][2] Group 1: Industry Trends - Recent large transactions in the BD sector highlight the rapid development of domestic biotech companies, which are playing a crucial role in driving global innovation [2] - Biotech companies are expanding into global markets through various methods such as license-out agreements, establishing overseas operational entities, or forming joint ventures, which involve complex tax considerations [2][3] Group 2: Tax Planning and Compliance - The tax costs and considerations associated with BD transactions are critical for maximizing value, necessitating prior planning of global IP arrangements based on commercial needs, feasibility, R&D costs, and new international tax rules [3] - The OECD's Pillar Two global minimum tax initiative is reshaping cross-border profit distribution and is directly linked to global investment and operational strategies of companies [2][4] Group 3: Regulatory Developments - The BEPS 2.0 Pillar Two international tax rules emphasize economic substance and are becoming a clear trend in international taxation, with increasing scrutiny from overseas tax authorities on the reasonableness of related-party transactions [4][5] - Although Chinese regulations are not yet in place, life sciences companies are already facing stricter international tax compliance requirements as they expand abroad [5]